查看2017.HSA.doxorubicin.AC.vs.ADTIC的源代码
←
2017.HSA.doxorubicin.AC.vs.ADTIC
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
=== 安全 (Safety) === 对所有狗的毒性进行了评估。在第 1 组中,共评估了 77 例全血细胞计数; '''中性粒细胞减少是唯一的骨髓毒性类型''',发生在六只 (33.3%) 狗身上。五只狗发生 1 级中性粒细胞减少症,而一只狗患上了 3 级中性粒细胞减少症 非发热性中性粒细胞减少症。在所有狗中,中性粒细胞减少症在第一次治疗后发生,并且在没有后遗症的情况下消退。没有进一步的血液学毒性记录。在第 2 组中,共评估了 96 例 CBC;中性粒细胞减少是唯一的骨髓毒性类型,发生在 7 只 (77.7%) 狗中,发生在化疗第 1 天后 10 天。一只狗发生两次 1 级中性粒细胞减少症,五只狗发生 6 次 2 级中性粒细胞减少症,两只狗发生 4 次 3 级中性粒细胞减少症,一只狗发生 1 次 4 级非发热性中性粒细胞减少症。两只狗在每个周期后出现中性粒细胞减少症,两只狗在第三个周期后出现中性粒细胞减少症,两只狗在治疗期间只有一次中性粒细胞减少症发作。其中,1 例在第二个周期后出现2级发热性中性粒细胞减少症,对症治疗后平安无事。发生中性粒细胞减少症之前给药的中位周期数为 2(范围:1-2 个周期),狗出现中性粒细胞减少症的中位周期数为 3(范围:1-4 个周期)。在所有狗中,中性粒细胞减少症在没有后遗症的情况下得到解决。 '''接受 ADTIC 的狗中性粒细胞减少的频率高于接受 AC 的狗'''(分别为 7 例中的 9 只 (77.8%) 和 6 例中的 18 例 (33.3%);P =0.046)。'''胃肠道毒性是两组中第二常见的不良事件,包括呕吐和食欲下降'''。第 1 组 7 只(38.8%)狗发生胃肠道毒性:2 只狗有 1 级副作用(1 只同时有 1 级中性粒细胞减少症),4 只狗有 2 级( 2 只同时有 1 级中性粒细胞减少症),1 只狗有 3 级毒性。在每种情况下,都记录了一次胃肠道毒性发作。在第 2 组中,三只 (33.3%) 狗出现胃肠道毒性;两只狗有 1 级(一只同时有 1 级中性粒细胞减少症),一只有 2 级毒性。胃肠道副作用的发生率在各组之间没有差异(P=1.000)。'''在第四个周期结束时,第 1 组中的一只狗出现脱发。'''没有记录到其他毒性。 All dogs were evaluated for toxicity. In group 1, a total of 77 CBCs were evaluated; neutropenia was the only type of bone marrow toxicity, occurring in six (33.3%) dogs. Grade 1 neutropenia occurred in five dogs, whereas one dog developed a grade-3 non-febrile neutropenia. In all dogs, neutropenia developed after the first treatment and resolved without sequel. No further hematological toxicities were recorded. In group 2, a total of 96 CBCs were evaluated; neutropenia was the only type of bone marrow toxicity, occurring in 7 (77.7%) dogs, 10 days after day 1 of chemotherapy. Two episodes of grade 1 neutropenia occurred in one dog, six episodes of grade 2 neutropenia occurred in five dogs, four episodes of grade 3 neutropenia occurred in two dogs and one episode of grade 4 non-febrile neutropenia occurred in one dog. Two dogs developed neutropenia after each cycle, two dogs after the third cycle and two dogs had only one episode of neutropenia during treatment. Among them, one developed a grade 2 febrile neutropenia after the second cycle, which resolved uneventfully after symptomatic treatment. The median number of cycles administered before developing neutropenia was 2 (range: 1–2 cycles), and the median number of cycles with dogs showing neutropenia was 3 (range: 1–4 cycles). In all dogs, neutropenia resolved without sequel. The frequency of neutropenia was higher in dogs that received ADTIC than in those that received AC (7 of 9 (77.8%) versus 6 of 18 (33.3%), respectively; P =0.046). Gastrointestinal toxicity was the second most common adverse event in both groups, which consisted of vomiting and decreased appetite. Gastrointestinal toxicity occurred in seven (38.8%) dogs in group 1: two dogs had grade 1 side effects (one concurrently had grade 1 neutropenia), four dogs had grade 2 (2 concurrently had grade 1 neutropenia) and one dog had grade 3 toxicity. In every case, a single episode of gastrointestinal toxicity was recorded. In group 2, three (33.3%) dogs developed gastrointestinal toxicity; two dogs had grade 1 (one concurrently had grade 1 neutropenia) and one had grade 2 toxicity. The frequency of gastrointestinal side effects did not differ between groups (P =1.000). Alopecia occurred in one dog in group 1 at the end of the fourth cycle. No other toxicities were recorded. <br>
返回到
2017.HSA.doxorubicin.AC.vs.ADTIC
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面